These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 20955264)

  • 61. Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness.
    Akaza H
    Cancer Sci; 2011 Jan; 102(1):51-6. PubMed ID: 21091846
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
    Blackledge G; Kolvenbag G; Nash A
    Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.
    Petit JH; Gluck C; Kiger WS; Henry DL; Karasiewicz C; Talcott J; Berg S; Holupka E; Kaplan I
    Urol Oncol; 2008; 26(4):372-7. PubMed ID: 18367113
    [TBL] [Abstract][Full Text] [Related]  

  • 64. No long-term effects of hormonal therapy preceding brachytherapy on urinary function and health-related quality of life among prostate cancer patients.
    Evers J; Kupper N; Kessing D; Davits R; Engelen A; Poortmans P; Mols F
    Urology; 2010 Nov; 76(5):1150-6. PubMed ID: 20869105
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Antiandrogen in prostate cancer].
    Maeda O; Usami M
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
    [No Abstract]   [Full Text] [Related]  

  • 66. Circadian rhythm of hot flashes and activity levels among prostate cancer patients on androgen deprivation therapy.
    Hanisch LJ; Gehrman PR
    Aging Male; 2011 Dec; 14(4):243-8. PubMed ID: 21627561
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Management of gynecomastia induced by bicalutamide].
    Haddad E
    Ann Urol (Paris); 2006 Dec; 40 Suppl 2():S49-52. PubMed ID: 17361921
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bicalutamide treatment for locally advanced prostate cancer.
    Anderson J
    Hosp Med; 2000 Sep; 61(9):660-3. PubMed ID: 11048610
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [DRUG-INDUCED INTERSTITIAL LUNG DISEASE DURING COMBINED ANDROGEN BLOCKADE WITH BICALUTAMIDE AND LEUPRORELIN ACETATE FOR PROSTATE CANCER].
    Maeda K; Osafune T; Masuda Y; Takeda T; Kageyama S; Narita M; Kawauchi A
    Nihon Hinyokika Gakkai Zasshi; 2019; 110(1):36-40. PubMed ID: 31956217
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Editorial comment to Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
    Yoshida T
    Int J Urol; 2013 Jul; 20(7):714-5. PubMed ID: 23216631
    [No Abstract]   [Full Text] [Related]  

  • 71. Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer?
    Boccon-Gibod L
    Eur Urol; 1998; 33(2):159-64. PubMed ID: 9519357
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Drug-related hepatotoxicity and hepatic failure following combined androgen blockade.
    Castro Beza I; Sánchez Ruiz J; Peracaula Espino FJ; Villanego Beltrán MI
    Clin Transl Oncol; 2008 Sep; 10(9):591-2. PubMed ID: 18796378
    [TBL] [Abstract][Full Text] [Related]  

  • 73. An unusual case of "sterile" abscess within low-grade meningioma during anti androgenic therapy and LH-releasing hormone agonist treatment for prostate cancer.
    Fabbri VP; Asioli S; Palandri G
    Clin Neurol Neurosurg; 2020 Sep; 196():105993. PubMed ID: 32563976
    [No Abstract]   [Full Text] [Related]  

  • 74. Effect of Casodex on sleep-related erections in patients with advanced prostate cancer.
    Migliari R; Muscas G; Usai E
    J Urol; 1992 Aug; 148(2 Pt 1):338-41. PubMed ID: 1378907
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bicalutamide with radiotherapy for prostate cancer.
    Brower V
    Lancet Oncol; 2017 Mar; 18(3):e141. PubMed ID: 28190764
    [No Abstract]   [Full Text] [Related]  

  • 76. Safety, side effects and patient acceptance of the antiandrogen Casodex in the treatment of benign prostatic hyperplasia.
    Eri LM; Tveter KJ
    Eur Urol; 1994; 26(3):219-26. PubMed ID: 7528662
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators.
    Tyrrell CJ
    Eur Urol; 1994; 26 Suppl 1():15-9. PubMed ID: 7537664
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy.
    Ham WS; Cho NH; Kim WT; Ju HJ; Lee JS; Choi YD
    J Urol; 2009 Oct; 182(4):1378-84. PubMed ID: 19683286
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Interstitial pneumonitis induced by bicalutamide given for prostate cancer.
    Masago T; Watanabe T; Nemoto R; Motoda K
    Int J Clin Oncol; 2011 Dec; 16(6):763-5. PubMed ID: 21537882
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment of locally advanced prostate cancer--a new role for antiandrogen monotherapy?
    Abrahamsson PA
    Eur Urol; 2001; 39 Suppl 1():22-8. PubMed ID: 11114597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.